Pfizer Limited

NSEI:PFIZER Stock Report

Market Cap: ₹199.4b

Pfizer Valuation

Is PFIZER undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PFIZER when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
₹1.89k
Fair Value
130.8% overvalued intrinsic discount
3
Number of Analysts

Below Fair Value: PFIZER (₹4357.9) is trading above our estimate of fair value (₹1888.54)

Significantly Below Fair Value: PFIZER is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PFIZER?

Key metric: As PFIZER is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for PFIZER. This is calculated by dividing PFIZER's market cap by their current earnings.
What is PFIZER's PE Ratio?
PE Ratio32.4x
Earnings₹6.16b
Market Cap₹199.36b

Price to Earnings Ratio vs Peers

How does PFIZER's PE Ratio compare to its peers?

The above table shows the PE ratio for PFIZER vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average65.7x
CONCORDBIO Concord Biotech
74.8x27.0%₹245.4b
EMCURE Emcure Pharmaceuticals
37.8x24.3%₹229.7b
SUVENPHAR Suven Pharmaceuticals
121.2xn/a₹294.7b
APLLTD Alembic Pharmaceuticals
28.8x24.9%₹174.3b
PFIZER Pfizer
32.4x11.0%₹199.4b

Price-To-Earnings vs Peers: PFIZER is good value based on its Price-To-Earnings Ratio (32.4x) compared to the peer average (65.7x).

Price to Earnings Ratio vs Industry

How does PFIZER's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
1.6xn/aUS$69.62m
524652 Ind-Swift
1.5xn/aUS$9.61m
No more companies available in this PE range
PFIZER 32.4xIndustry Avg. 31.9xNo. of Companies18PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: PFIZER is expensive based on its Price-To-Earnings Ratio (32.4x) compared to the Indian Pharmaceuticals industry average (31.9x).

Price to Earnings Ratio vs Fair Ratio

What is PFIZER's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PFIZER PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio32.4x
Fair PE Ratio30.3x

Price-To-Earnings vs Fair Ratio: PFIZER is expensive based on its Price-To-Earnings Ratio (32.4x) compared to the estimated Fair Price-To-Earnings Ratio (30.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PFIZER forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹4,357.90
₹5,623.33
+29.0%
16.8%₹6,900.00₹4,640.00n/a3
Jan ’26₹5,307.45
₹5,935.00
+11.8%
14.8%₹7,175.00₹5,300.00n/a3
Dec ’25₹5,313.25
₹5,935.00
+11.7%
14.8%₹7,175.00₹5,300.00n/a3
Nov ’25₹5,159.40
₹5,935.00
+15.0%
14.8%₹7,175.00₹5,300.00n/a3
Oct ’25₹5,562.50
₹5,935.00
+6.7%
14.8%₹7,175.00₹5,300.00n/a3
Sep ’25₹6,065.05
₹5,935.00
-2.1%
14.8%₹7,175.00₹5,300.00n/a3
Aug ’25₹5,640.35
₹5,476.67
-2.9%
4.2%₹5,800.00₹5,300.00n/a3
Jul ’25₹4,602.30
₹4,975.00
+8.1%
6.0%₹5,330.00₹4,595.00n/a3
Jun ’25₹4,609.75
₹4,953.33
+7.5%
6.1%₹5,330.00₹4,595.00n/a3
May ’25₹4,257.20
₹4,720.33
+10.9%
8.0%₹5,036.00₹4,190.00n/a3
Apr ’25₹4,448.35
₹4,720.33
+6.1%
8.0%₹5,036.00₹4,190.00n/a3
Mar ’25₹4,589.95
₹4,720.33
+2.8%
8.0%₹5,036.00₹4,190.00n/a3
Feb ’25₹4,578.20
₹4,526.33
-1.1%
7.5%₹4,954.00₹4,125.00₹4,562.853
Jan ’25₹4,267.50
₹4,352.25
+2.0%
9.7%₹4,954.00₹3,830.00₹5,307.454
Dec ’24₹4,101.40
₹4,441.80
+8.3%
9.4%₹4,954.00₹3,830.00₹5,313.255
Nov ’24₹3,883.25
₹4,441.80
+14.4%
9.4%₹4,954.00₹3,830.00₹5,159.405
Oct ’24₹3,859.65
₹4,441.80
+15.1%
9.4%₹4,954.00₹3,830.00₹5,562.505
Sep ’24₹3,815.55
₹4,441.80
+16.4%
9.4%₹4,954.00₹3,830.00₹6,065.055
Aug ’24₹4,023.50
₹4,460.00
+10.8%
8.6%₹4,800.00₹3,830.00₹5,640.355
Jul ’24₹3,777.15
₹4,460.00
+18.1%
8.6%₹4,800.00₹3,830.00₹4,602.305
Jun ’24₹3,810.25
₹4,595.00
+20.6%
4.9%₹4,800.00₹4,200.00₹4,609.755
May ’24₹3,751.65
₹4,988.40
+33.0%
8.3%₹5,500.00₹4,505.00₹4,257.205
Apr ’24₹3,467.15
₹4,988.40
+43.9%
8.3%₹5,500.00₹4,505.00₹4,448.355
Mar ’24₹3,811.20
₹4,988.40
+30.9%
8.3%₹5,500.00₹4,505.00₹4,589.955
Feb ’24₹3,821.15
₹5,179.40
+35.5%
6.9%₹5,500.00₹4,505.00₹4,578.205
Analyst Price Target
Consensus Narrative from 3 Analysts
₹5.62k
Fair Value
22.5% undervalued intrinsic discount
3
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 18:57
End of Day Share Price 2025/02/07 00:00
Earnings2024/12/31
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Pfizer Limited is covered by 13 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sriraam RathiAnand Rathi Shares and Stock Brokers Limited
null nullAnand Rathi Shares and Stock Brokers Limited
Rohit BhatBatlivala & Karani Securities India Pvt. Ltd.